Latest News and Press Releases
Want to stay updated on the latest news?
-
Photys Therapeutics exclusively in-licensed Phase 1-ready IRAK4 degrader from Polymed; plan to start Phase 1 later this year for autoimmune indications
-
Photys and Novo Nordisk established a research collaboration to discover a new class of medicine for cardiometabolic diseases.